Recent Pfizer Press Releases

  • 8/17/17 1:57 pm EDT

    BESPONSA is the first and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).1 BESPONSA was reviewed and approved under the FDA’s Breakthrough Therapy designation and Priority Review programs. “The approval of BESPONSA is an important step forward for adult patientsmore...
  • 8/3/17 2:10 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee (AAC) voted 10 to 1 to recommend approval of the proposed dose of tofacitinib for the treatment of adult patients with active psoriatic arthritis (PsA). Pfizer submitted supplemental new drug applications (sNDAs) for XELJANZ® 5 mg twice daily (BID) and XELJANZ® XR extended release 11 mg once daily (QD) for this pending indicationmore...
  • 8/1/17 6:45 am EDT
    • Second-Quarter 2017 Revenues of $12.9 Billion, Comparable Operationally with the Prior-Year Quarter; Unfavorably Impacted by $295 Million, or 2%, Due to the February 2017 Divestiture of Hospira Infusion Systems
    • Second-Quarter 2017 Reported Diluted EPS(1) of $0.51, Adjusted Diluted EPS(2) of $0.67
    • Raised Midpoint of 2017 Adjusted Diluted EPS(2) Guidance Range by $0.02 to a Range of $2.54 to $2.60; Reaffirmed 2017 Revenue Guidance Range of $52.0 to $54.0 Billion
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for second-quarter 2017, increased the midpoint of its 2017 financial guidance range for Adjusted diluted EPS(2) and reaffirmed its 2017 financial guidance range for Revenues. Results for the second quarter and first six months of 2017 and 2016(3) are summarized below. OVERALL RESULTSmore...
  • 7/24/17 8:30 am EDT

    Results demonstrate equivalence in objective response rate in patients with advanced non-squamous non-small cell lung cancer

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin® (bevacizumab), met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin. The trial demonstrated equivalence in the primary endpoint of objective response rate (ORR) of PF-06439535 versus Avastin, taken in combination withmore...
  • 7/20/17 1:23 am EDT
    NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, today announced they have completed the licensing agreement whereby Pfizer has obtained the exclusive commercialization rights in Europe to CRESEMBA (isavuconazole), a novel anti-fungal treatment for adult patients with diagnosed invasivemore...
  • 7/13/17 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis (UC), has been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in March 2018 for the sNDA. “more...
  • 7/11/17 4:32 pm EDT

    Committee votes 6-1 that MYLOTARG in combination with chemotherapy has a favorable risk:benefit profile for patients with newly-diagnosed CD33-positive AML

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk:benefit profile for MYLOTARG (gemtuzumab ozogamicin) 3 mg/m2 on days 1, 4 and 7 added to chemotherapy for patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML). The role of the Advisory Committee is to provide recommendations to themore...
  • 6/30/17 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). This indication includes treatment of adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell precursor ALL. Adults withmore...
  • 6/27/17 9:00 am EDT

    Builds on 15-year history in Missouri

    Supported by local and state incentives, anticipated job growth

    ST. LOUIS--(BUSINESS WIRE)--Today Pfizer Inc., (NYSE:PFE) one of the world’s premier biopharmaceutical companies, broke ground on a state-of-the art Research and Development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield, MO. The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the St. Louis area. Pfizer expects to hire anmore...
  • 6/22/17 4:05 pm EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 32-cent third-quarter 2017 dividend on the company’s common stock, payable September 1, 2017, to shareholders of record at the close of business on August 4, 2017. The third-quarter 2017 cash dividend will be the 315th consecutive quarterly dividend paid by Pfizer. Working together for a healthier world® At Pfizer, we apply science and our global resources to bringmore...